Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.63 |
| ▸ | HMGCR | P04035 | 4/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.63 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | RHOC | P08134 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.51 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.51 |
| ▸ | PDE6D | O43924 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12060159 | 1.00 | SLCO1B1 (0.63) | SLCO1B1HMGCRABCB1ABCC2ABCB11 | |
| SCHEMBL915694 | 0.94 | SLCO1B1 (0.63) | SLCO1B1HMGCRABCB1ABCC2ABCB11 | |
| SCHEMBL5607310 | 0.94 | SLCO1B1 (0.63) | SLCO1B1HMGCRABCB1ABCC2ABCB11 | |
| SCHEMBL12059856 | 0.93 | HMGCR (0.61) | SLCO1B1HMGCRABCB1ABCC2ABCB11 | |
| SCHEMBL14748354 | 0.93 | HMGCR (0.61) | SLCO1B1HMGCRABCB1ABCC2ABCB11 | |
| SCHEMBL12045341 | 0.93 | HMGCR (0.61) | SLCO1B1HMGCRABCB1ABCC2ABCB11 | |
| SCHEMBL14748399 | 0.93 | HMGCR (0.61) | SLCO1B1HMGCRABCB1ABCC2ABCB11 | |
| SCHEMBL5607092 | 0.92 | SLCO1B1 (0.66) | SLCO1B1HMGCRABCB1ABCC2ABCB11 | |
| SCHEMBL12060156 | 0.91 | HMGCR (0.59) | SLCO1B1HMGCRABCB1ABCC2ABCB11 | |
| SCHEMBL14748398 | 0.91 | HMGCR (0.59) | SLCO1B1HMGCRABCB1ABCC2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006282-B2 | Rosuvastatin and atorvastatin derivatives | REDX PHARMA LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-9006282-B2 | Rosuvastatin and atorvastatin derivatives | REDX PHARMA LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| EP-2614822-B1 | Atorvastatin Derivatives | REDX PHARMA LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20130303773-A1 | Rosuvastatin and Atorvastatin Derivatives | REDX PHARMA PLC (GB) | 2013-11-14 | — | — | US | disclosed |
| US-20130303773-A1 | Rosuvastatin and Atorvastatin Derivatives | REDX PHARMA PLC (GB) | 2013-11-14 | — | — | US | disclosed |
| EP-2405910-B1 | Rosuvastatin and atorvastatin derivatives | REDX PHARMA LTD (GB) | 2013-09-04 | — | — | EP | disclosed |
| US-8513412-B2 | Rosuvastatin and atorvastatin derivatives | RedX Pharna Limited (GB) | 2013-08-20 | — | — | US | disclosed |
| US-8513412-B2 | Rosuvastatin and atorvastatin derivatives | RedX Pharna Limited (GB) | 2013-08-20 | — | — | US | disclosed |
| EP-2614822-A2 | Atorvastatin Derivatives | Redx Pharma Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| EP-2405911-B1 | USE OF ATORVASTATIN LACTOLS AS MEDICAMENTS | REDX PHARMA LTD (GB) | 2013-03-06 | — | — | EP | disclosed |
| US-20110319617-A1 | Rosuvastatin and Atorvastatin Derivatives | BRADFORD PHARMA LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
| US-20110319626-A1 | Use of Atorvastatin Lactols as Medicaments | BRADFORD PHARMA LIMITED (GB) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319617-A1 | Rosuvastatin and Atorvastatin Derivatives | HMGCR, PCSK9, SREBF1 | SLCO1B1 420/4885HMGCR 1/4885ABCB1 625/4885 |
| US-20130303773-A1 | Rosuvastatin and Atorvastatin Derivatives | HMGCR, PCSK9, SREBF1 | SLCO1B1 420/4885HMGCR 1/4885ABCB1 625/4885 |
| US-20110319626-A1 | Use of Atorvastatin Lactols as Medicaments | HMGCR, PCSK9, LIPA | SLCO1B1 723/4885HMGCR 1/4885ABCB1 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.